Updated:
Ocugen
Ocugen is a biotech company based in Aurora, United States, founded in 2013. It specializes in vaccines and gene therapies, focusing on public health and unmet...
Ocugen
Ocugen is a biotech company based in Aurora, United States, founded in 2013. It specializes in vaccines and gene therapies, focusing on public health and unmet medical needs. The company's platform includes a modifier gene therapy for multiple retinal diseases and ongoing research in COVID-19 vaccine development, with $23.82 million in total funding.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Malvern
Corporate office
Malvern, United States
Frequently asked questions
What is Ocugen's primary therapeutic focus?
Ocugen is developing modifier gene therapies for retinal diseases, with lead candidate OCU400 targeting retinitis pigmentosa. The firm also collaborated on a COVID-19 vaccine candidate (Covaxin) through a partnership with Bharat Biotech (per company communications, 2022).
How does Ocugen's modifier gene therapy differ from other gene therapies?
Ocugen's modifier therapy platform aims to restore cellular function across multiple downstream pathways without correcting a specific gene mutation. This contrasts with gene replacement therapies that are disease- or mutation-specific and may have limited applicability across patient populations.
Which partners support Ocugen's manufacturing and distribution?
Ocugen has partnered with Bharat Biotech, an Indian vaccine manufacturer, for Covaxin development and supply. The company has not disclosed other manufacturing partners for its gene therapy programs beyond general contract manufacturing arrangements.
Has Ocugen disclosed its AUM or deployment amount?
No. Ocugen does not publicly report assets under management or deployment figures. The firm funds R&D through equity offerings and strategic partnerships, as disclosed in SEC filings.
What stage of clinical development is Ocugen in?
Ocugen's lead candidate OCU400 was in Phase 3 clinical trials as of 2023, with initial data expected in 2024. The firm also explored regulatory approval for Covaxin under an emergency use authorization pathway in the US.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: